- $38.43m
- $35.79m
- $8.50m
Brief: Apollomics’ Announces Shareholder Approval And Effective Date For 1-For-100 Reverse Share Split
U.S. STOCKS ON THE MOVE-Paysafe, HUYA, Oklo
U.S. STOCKS ON THE MOVE-Penumbra, Talen Energy, Paysafe
U.S. STOCKS ON THE MOVE-Apollomics, Syros Pharmaceuticals, Buzzfeed
Apollomics rises on positive preliminary data from cancer therapy study
Brief: Apollomics Granted 180-Day Extension To Regain Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Apollomics Expects Over 50% Reduction In Ongoing Expenses
Brief: Apollomics Entered Sales Agreement To Offer Co's Class A Ordinary Shares Having Aggregate Offering Price Of Up To $19 Mln
Brief: Apollomics Inc Pipe Subscription Agreements For A Private Placement With Certain Accredited Investors
Brief: Apollomics Announces Approval Of Vebreltinib In China
Brief: Apollomics Inc Files For Mixed Shelf Of Up To $200 Million – SEC Filing
Brief: Apollomics Highlights Clinical Progress And Reports Full Year 2023 Results
Brief: Apollomics Appoints Matthew Plunkett As CFO
Brief: Apollomics Says Co Received Nasdaq Notification Regarding Minimum Bid Price Deficiency
Brief: Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
Brief: Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
Apollomics gains as partner gets conditional nod for lung cancer drug in China
U.S. STOCKS ON THE MOVE-Macy's, Squarespace, Bath & Body Works
Brief: Apollomics Announces Two New Cohorts In Global Phase 2 Sparta Study Of Vebreltinib In Non-Small Cell Lung Cancer And Other Solid Tumors With Met Dysregulation